» Articles » PMID: 31351194

Prospective Assessment of Patient-Reported Dry Eye Syndrome After Whole Brain Radiation

Abstract

Purpose: Dry eye is not typically considered a toxicity of whole brain radiation therapy (WBRT). We analyzed dry eye syndrome as part of a prospective study of patient-reported outcomes after WBRT.

Methods And Materials: Patients receiving WBRT to 25 to 40 Gy were enrolled on a study with dry mouth as the primary endpoint and dry eye syndrome as a secondary endpoint. Patients received 3-dimensional WBRT using opposed lateral fields. Per standard practice, lacrimal glands were not prospectively delineated. Patients completed the Subjective Evaluation of Symptom of Dryness (SESoD, scored 0-4, with higher scores representing worse dry eye symptoms) at baseline, immediately after WBRT (EndRT), and at 1 month (1M), 3 months, and 6 months. Patients with baseline SESoD ≥3 (moderate dry eye) were excluded. The endpoints analyzed were ≥1-point and ≥2-point increase in SESoD score at 1M. Lacrimal glands were retrospectively delineated with fused magnetic resonance imaging scans.

Results: One hundred patients were enrolled, 70 were eligible for analysis, and 54 were evaluable at 1M. Median bilateral lacrimal V20Gy was 79%. At 1M, 17 patients (32%) had a ≥1-point increase in SESoD score, and 13 (24%) a ≥2-point increase. Lacrimal doses appeared to be associated with an increase in SESoD score of both ≥1 point (V10Gy: P = .042, odds ratio [OR] 1.09/%; V20Gy: P = .071, OR 1.03/%) and ≥2 points (V10Gy: P = .038, OR 1.15/%; V20Gy: P = .063, OR 1.04/%). The proportion with increase in dry eye symptoms at 1M for lacrimal V20Gy ≥79% versus <79% was 46% versus 15%, respectively, for ≥1 point SESoD increase (P = .02) and 36% versus 12%, respectively, for ≥2 point SESoD increase (P = .056).

Conclusions: Dry eye appears to be a relatively common, dose/volume-dependent acute toxicity of WBRT. Minimization of lacrimal gland dose may reduce this toxicity, and patients should be counseled regarding the existence of this potential side effect and treatments for dry eye.

Citing Articles

Mask dependency of the lacrimal gland dose under whole brain radiotherapy when the six-degrees of freedom couch is not available.

Yoon J, Kim M, Park S, Cheong K, Kang S, Koo T J Appl Clin Med Phys. 2023; 24(7):e14052.

PMID: 37254709 PMC: 10338750. DOI: 10.1002/acm2.14052.


Ocular Surface Changes in Treatment-Naive Thyroid Eye Disease.

Liao X, Lai K, Aljufairi F, Chen W, Hu Z, Man Wong H J Clin Med. 2023; 12(9).

PMID: 37176507 PMC: 10179143. DOI: 10.3390/jcm12093066.


Hybrid split-arc partial-field volumetric modulated arc therapy: an improved beam arrangement for linear accelerator-based hippocampal-avoidance whole brain radiation therapy.

Yuen A, Wu P, Li A, Mak P Rep Pract Oncol Radiother. 2022; 27(2):352-359.

PMID: 36299387 PMC: 9591038. DOI: 10.5603/RPOR.a2022.0022.


OSDI Questions on Daily Life Activities Allow to Detect Subclinical Dry Eye in Young Contact Lens Users.

Pastor-Zaplana J, Borras F, Gallar J, Acosta M J Clin Med. 2022; 11(9).

PMID: 35566752 PMC: 9101005. DOI: 10.3390/jcm11092626.


NTCP modeling and dose-volume correlations for acute xerostomia and dry eye after whole brain radiation.

Mavroidis P, Pearlstein K, Moon D, Xu V, Royce T, Weiner A Radiat Oncol. 2021; 16(1):56.

PMID: 33743773 PMC: 7981795. DOI: 10.1186/s13014-021-01786-6.


References
1.
Hoebers F, Kartachova M, de Bois J, van den Brekel M, van Tinteren H, Van Herk M . 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2007; 35(3):509-18. PMC: 2275773. DOI: 10.1007/s00259-007-0624-x. View

2.
Letschert J, Gonzalez Gonzalez D, Oskam J, Koornneef L, van Dijk J, Boukes R . Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiother Oncol. 1991; 22(1):36-44. DOI: 10.1016/0167-8140(91)90067-q. View

3.
Wu C, Wuu Y, Jani A, Saraf A, Tai C, Lapa M . Whole-brain Irradiation Field Design: A Comparison of Parotid Dose. Med Dosim. 2017; 42(2):145-149. DOI: 10.1016/j.meddos.2017.02.006. View

4.
Stephens L, Schultheiss T, Price R, Ang K, Peters L . Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer. 1991; 67(6):1539-43. DOI: 10.1002/1097-0142(19910315)67:6<1539::aid-cncr2820670613>3.0.co;2-q. View

5.
Nutting C, Morden J, Harrington K, Urbano T, Bhide S, Clark C . Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2):127-36. PMC: 3033533. DOI: 10.1016/S1470-2045(10)70290-4. View